---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-032969"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-10-20T11:00:28+00:00"
generated_at: "2026-10-20T11:05:17.464368+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech sets 1-for-20 reverse split effective Oct 20, 2026; shares outstanding fall to ~1.05M

## Summary
- Board approved 1-for-20 reverse split after stockholders authorized a ratio of 1-for-2 to 1-for-20 at the Oct 9, 2026 annual meeting.
- Split effective 12:01 a.m. ET Oct 20, 2026; MBRX trades post-split on Nasdaq Capital Market with new CUSIP 60855D507.
- Outstanding shares drop from ~20.91 million to ~1.05 million; authorized shares stay at 500 million; par value unchanged at $0.001.
- No fractional shares issued — holders receive cash equal to the fraction times the 5-day average closing price before the split.
- Restated post-split FY2025 net loss per share $(568.38) vs pre-split $(28.42); net loss $33.56M in FY2025 vs $26.05M in FY2024.

## SEC filing metadata
- accession: 0001437749-26-032969
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-10-20T11:00:28+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926032969/0001437749-26-032969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926032969/mbrx20261015d_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-032969
- JSON: https://secwatch.observer/filing/0001437749-26-032969.json
- Plain text: https://secwatch.observer/filing/0001437749-26-032969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.